Dyadic (NASDAQ:DYAI) has expanded its strategic collaboration with Fermbox Bio to enhance the manufacturing, commercialization, and dual-sourcing of animal-free proteins and enzymes developed by Dyadic.
The broader partnership aims to accelerate the production and distribution of these biotechnological solutions across multiple markets, including life sciences, food and nutrition, and bioindustries.
Under the expanded agreement, Fermbox Bio will scale the manufacturing of Dyadic-origin products at a commercial level.
Both companies will now have global co-commercialization rights, enabling them to jointly market the animal-free proteins and enzymes.
Additionally, the collaboration will include Fermbox-developed products, integrating them into the joint portfolio to broaden their offerings.
A key aspect of the partnership is the dual-sourcing arrangement via Dyadic's C1, Dapibus™, or alternative microbial systems, ensuring supply chain flexibility.
Both companies have committed to managing a continually updated product pipeline, designed to streamline development and accelerate commercialization timelines.